Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History XFOR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics XFOR

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

X4 Pharmaceuticals Inc

XFOR
Current price
1.69 USD -0.2 USD (-10.37%)
Last closed 1.89 USD
ISIN US98420X1037
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 13 567 856 USD
Yield for 12 month -90.54 %
1Y
3Y
5Y
10Y
15Y
XFOR
21.11.2021 - 28.11.2021

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally bioavailable selective antagonist of chemokine receptor C-X-C chemokine receptor type 4 (CXCR4) for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. The company also develops mavorixafor that is in Phase 3 4WARD clinical trial to evaluate the efficacy, safety, and tolerability of oral, once-daily mavorixafor with or without stable doses of G-CSF in people with congenital, acquired primary autoimmune, or idiopathic CN who are experiencing recurrent and/or serious infections. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications; and with Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand. The company is headquartered in Boston, Massachusetts. Address: 61 North Beacon Street, Boston, MA, United States, 02134

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

42.67 USD

P/E Ratio

0.90

Dividend Yield

Financials XFOR

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures XFOR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+2 557 000 USD

Last Year

Current Quarter

+28 807 000 USD

Last Quarter

+1 434 000 USD

Current Year

+1 760 000 USD

Last Year

-1 996 000 USD

Current Quarter

+24 091 000 USD

Last Quarter

+1 132 000 USD
EBITDA -112 345 000 USD
Operating Margin TTM -32.78 %
Price to Earnings 0.90
Return On Assets TTM -58.61 %
PEG Ratio
Return On Equity TTM 121.75 %
Wall Street Target Price 42.67 USD
Revenue TTM 31 364 000 USD
Book Value 3.96 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM 25 851 000 USD
Earnings per share 2.11 USD
Diluted Eps TTM 2.11 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin 46.54 %

Stock Valuation XFOR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 0.90
Forward PE
Enterprise Value Revenue 0.15
Price Sales TTM 0.43
Enterprise Value EBITDA 0.18
Price Book MRQ 0.59

Technical Indicators XFOR

For 52 Weeks

1.81 USD 26.97 USD
50 Day MA 3.30 USD
Shares Short Prior Month 396 893
200 Day MA 11.66 USD
Short Ratio 1.64
Shares Short 484 831
Short Percent 8.50 %